PolyPid Ltd.

118 articles about PolyPid Ltd.

• PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference

  2/28/2024

  PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes, announced that Company management will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference taking place in Miami Beach, FL, March 12 – 14, 2024.

• PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

  2/14/2024

  PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes, provided a corporate update and reported financial results for the three months and full year ended December 31, 2023.

• PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial

  2/12/2024

  PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has enrolled and randomized the 100th patient in its ongoing SHIELD II Phase 3 trial for D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery with large incisions.

• PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024

  1/31/2024

  PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 14, 2024.

• PolyPid Announces Private Placement for $16 Million in Gross ProceedsFinancing Led by Leading U.S. Life Sciences-focused Investors

  1/4/2024

  PolyPid Ltd. announced that it has entered into a securities purchase agreement for a private placement financing for $16.2 million in gross proceeds priced at the 5-day volume weighted average price as of January 2, 2024 of $4.81 per share.

• PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results

  11/8/2023

  PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three and nine months ended September 30, 2023.

• PolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023

  11/1/2023

  PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes, announced that it will report its third quarter 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 8, 2023.

• PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule - October 11, 2023

  10/11/2023

  PolyPid Ltd. announced that it has received a written notice from The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550, which requires listed securities, including the Company's ordinary shares, to maintain a minimum bid price of $1.00 per share.

• PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023

  10/9/2023

  PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes, announced that SHIELD I Phase 3 clinical data for D-PLEX100 will be highlighted in a presentation at the American College of Surgeons Clinical Congress 2023, to be held on October 22-25, 2023, in Boston, MA.

• PolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX₁₀₀ and PLEX Technology Platform

  10/4/2023

  PolyPid Ltd. today announced the publication of positive preclinical results demonstrating, for the first time, the safety profile of D-PLEX.

• PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

  9/22/2023

  PolyPid Ltd.  today announced that Company’s management will present at the Cantor Global Healthcare Conference taking place on September 26-28, 2023, in New York City, New York. Cantor Global Healthcare Conference.

• PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of Health

  9/21/2023

  PolyPid Ltd. today announced that the Israeli Ministry of Health has completed a successful Good Manufacturing Practice (GMP) audit of the Company's manufacturing facility without any critical or major findings.

• PolyPid Announces Reverse Share Split - September 20, 2023

  9/20/2023

  PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes, announces a reverse share split of the Company’s issued and outstanding ordinary shares, no par value, at the ratio of 1-for-30, such that each thirty Ordinary Shares, shall be consolidated into one Ordinary Share.

• PolyPid Announces Successful Completion of Manufacturing Process Validation for D-PLEX₁₀₀

  9/19/2023

  PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes, announced the successful completion of the production of three process validation batches of D-PLEX100 which have started stability program.

• PolyPid Provides Corporate Update and Reports Second Quarter 2023 Financial Results

  8/9/2023

  PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three and six months ended June 30, 2023.

• PolyPid to Report Second Quarter 2023 Financial Results and Operational Highlights on August 9, 2023

  7/26/2023

  PolyPid Ltd. today announced that it will report its second quarter 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 9, 2023.

• PolyPid Announces New Publication Highlighting Potent Antibacterial Activity of D-PLEX₁₀₀ against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections

  6/29/2023

  PolyPid Ltd. today announced a new publication highlighting the potent antibacterial activity of D-PLEX100 and its potential as an effective prophylactic drug against the most prevalent bacteria causing surgical site infections (SSIs), including resistant strains.

• PolyPid Announces Recruitment of First Patient in Revised SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections

  6/22/2023

  PolyPid Ltd. today announced that the first patient has been recruited and is scheduled for surgery in its revised SHIELD II Phase 3 trial evaluating D-PLEX 100 for the prevention of abdominal colorectal surgical site infections (SSIs).

• PolyPid Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement and Transfer of its Listing to the Nasdaq Capital Market

  6/5/2023

  PolyPid Ltd. announced it has received an extension of the period to regain compliance with The Nasdaq Stock Market LLC’s minimum bid price rule and approval from Nasdaq to transfer the listing of the ordinary shares of the Company from The Nasdaq Global Market to The Nasdaq Capital Market.

• PolyPid Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections

  5/22/2023

  PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) agreed to Company’s SHIELD II Phase 3 trial design evaluating D-PLEX100 for the prevention of abdominal colorectal surgical site infections (SSIs).